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ABSTRACT Group B Streptococcus (GBS) causes frequent urinary tract infection (UTI)
in susceptible populations, including individuals with type 2 diabetes and pregnant
women; however, specific host factors responsible for increased GBS susceptibility in
these populations are not well characterized. Here, we investigate cathelicidin, a cat-
ionic antimicrobial peptide, known to be critical for defense during UTI with uro-
pathogenic Escherichia coli (UPEC). We observed a loss of antimicrobial activity of
human and mouse cathelicidins against GBS and UPEC in synthetic urine and no evi-
dence for increased cathelicidin resistance in GBS urinary isolates. Furthermore, we
found that GBS degrades cathelicidin in a protease-dependent manner. Surprisingly,
in a UTI model, cathelicidin-deficient (Camp/) mice showed decreased GBS bur-
dens and mast cell recruitment in the bladder compared to levels in wild-type (WT)
mice. Pharmacologic inhibition of mast cells reduced GBS burdens and histamine re-
lease in WT but not Camp/ mice. Streptozotocin-induced diabetic mice had in-
creased bladder cathelicidin production and mast cell recruitment at 24 h postinfec-
tion with GBS compared to levels in nondiabetic controls. We propose that
cathelicidin is an important immune regulator but ineffective antimicrobial peptide
against GBS in urine. Combined, our findings may in part explain the increased fre-
quency of GBS UTI in diabetic and pregnant individuals.
IMPORTANCE Certain populations such as diabetic individuals are at increased risk
for developing urinary tract infections (UTI), although the underlying reasons for this
susceptibility are not fully known. Additionally, diabetics are more likely to become
infected with certain types of bacteria, such as group B Streptococcus (GBS). In this
study, we find that an antimicrobial peptide called cathelicidin, which is thought to
protect the bladder from infection, is ineffective in controlling GBS and alters the
type of immune cells that migrate to the bladder during infection. Using a mouse
model of diabetes, we observe that diabetic mice are more susceptible to GBS infec-
tion even though they also have more infiltrating immune cells and increased pro-
duction of cathelicidin. Taken together, our findings identify this antimicrobial pep-
tide as a potential contributor to increased susceptibility of diabetic individuals to
GBS UTI.
KEYWORDS cathelicidin, group B Streptococcus, innate immunity, mast cell, urinary
tract infection
Urinary tract infection (UTI) afflicts more than half of women at least once in theirlifetime and generates over $2.4 billion in health care costs annually in the United
States (1, 2). Acute UTI is typically mild, limited to the bladder (cystitis), and readily
treated in healthy adults, but individuals with underlying metabolic and/or immune
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dysfunction such as type 2 diabetes and gestational diabetes are at risk for complica-
tions, including recurrent UTI, ascending infection (pyelonephritis), and urosepsis (3–5).
While uropathogenic Escherichia coli (UPEC) is the predominant organism in UTI, group
B Streptococcus (GBS) accounts for 1 to 2% of UTIs (6, 7), and increased GBS incidence
in diabetic individuals has been reported in some cohorts (8) but not others (7, 9).
Diabetes is associated with increased GBS asymptomatic bacteriuria (10) and is a
leading risk factor for progression to invasive GBS disease (11–14). While the underlying
molecular pathways are not understood, this clinical phenomenon implies that the
urinary microenvironment may be altered to favor GBS colonization and dissemination
in diabetes.
Systematic review and meta-analyses indicate that GBS asymptomatically colonizes
18% of pregnant women globally (15), and individual studies support similar coloni-
zation rates among other populations (16, 17). GBS is widely recognized as an agent of
maternal infection and neonatal sepsis, and the highest incidence of GBS disease occurs
in the first week of life (18). Heavy GBS vaginal carriage or GBS bacteriuria is associated
with increased risk of preterm delivery and neonatal sepsis (19, 20). Current recom-
mendations for universal screening of pregnant women to guide intrapartum antibiotic
prophylaxis have reduced neonatal infections (18). However, 90% of GBS disease occurs
outside the perinatal period, and infections, including UTI, of both adult and elderly
populations are on the rise (12, 13, 18). Overall, GBS causes 160,000 UTIs annually in
the United States (21), which is perhaps an underestimation based on recent improve-
ments in culture techniques (22). GBS likely gains access to the female urinary tract
through vaginal colonization, and a higher prevalence of GBS colonization is found in
women with gestational diabetes (23–25), while the contribution of diabetes to GBS
urogenital colonization outside pregnancy has not been extensively examined (26, 27).
Effective host immune responses controlling GBS UTI are poorly characterized, and
urinary immune suppression by the bacterium has been reported (28–30).
Multiple immune cells infiltrate the bladder during UTI, including neutrophils,
monocytes, macrophages, dendritic cells, mast cells, CD4 T cells, and NK cells (31–34).
Additionally, multiple host factors protect against UTI through direct or indirect anti-
bacterial activity, including antimicrobial peptides (AMPs) such as cathelicidins and
-defensins, iron-binding proteins, and soluble proteins that inhibit bacterial attach-
ment (35–38). Many of these defense factors are subject to metabolic and hormonal
regulation changes that occur during diabetes or pregnancy (39–42). Additionally,
recent studies suggest that some, if not all, of these factors play immunomodulatory
roles in the bladder (43–45).
Cathelicidins, a family of cationic AMPs, are produced by immune and epithelial cells
and protect the host in part through direct killing of bacterial pathogens (46). Humans
and mice each produce only one cathelicidin: LL-37 (encoded by CAMP) and CRAMP
(encoded by Camp), respectively. Urinary cathelicidin levels increase dramatically dur-
ing UTI such that cathelicidin is a suitable UTI biomarker (47). Resistance to cathelicidin
killing is a hallmark of invasive UPEC isolates, and cathelicidin-deficient animals
(Camp/) display increased bacterial burdens and tissue damage in some models (46)
but not others (48), suggesting a complex role of cathelicidin in urinary tract protection.
The bladder epithelium is primed to release cathelicidin and appears to be the primary
source of the AMP during UTI (46). Cathelicidins are increasingly recognized as potent
immunomodulators that influence monocyte and neutrophil chemotaxis, reactive ox-
ygen species and cytokine production, and immune cell pattern recognition signaling
(49–51). Exogenous administration of human cathelicidin LL-37 itself instigates cystitis
in animal models (52, 53). Clinically, increased LL-37 levels are observed in GBS-
susceptible populations, including diabetic patients (54, 55) and pregnant women (41).
Additionally, the tissue microenvironment or in vitro medium testing conditions mark-
edly influence cathelicidin antimicrobial activity (56–58).
Here, we investigate the role of cathelicidin in the host response to GBS UTI. We
observe a loss of cathelicidin antimicrobial activity against GBS in urine and no selection
for cathelicidin resistance across GBS urinary isolates. Rather, we find that cathelicidin-
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deficient mice are better able to control GBS bladder burdens than wild-type (WT) mice,
in combination with reduced mast cell recruitment and degranulation. Using pharma-
cologic inhibition of mast cells and a streptozotocin (STZ)-induced diabetic murine
model, we further link mast cell recruitment with an inability to control GBS bladder
burdens. Combined, our findings may in part explain the increased frequency of GBS
UTI in diabetic and pregnant individuals while highlighting mast cells as a potential
therapeutic target in these patients.
RESULTS
Susceptibility to cathelicidin is similar for UPEC and GBS clinical isolates. To
compare the susceptibility of GBS and UPEC to cathelicidin, MIC assays were performed
with the widely studied GBS strain COH1, a hypervirulent sequence type 17 serotype III
isolate, and UPEC strain CFT073, a pyelonephritis isolate. Bacteria were incubated with
synthetic peptides for human LL-37 and murine CRAMP in tissue culture medium (RPMI
1640 medium) or synthetic urine (59) for 24 h. Due to lower optical densities of cultures
grown in synthetic urine, MICs were determined by a 90% reduction in fluorescent
signal from the conversion of resazurin to fluorescent resorufin, a sensitive readout of
bacterial metabolic activity (60, 61). In RPMI 1640 medium, LL-37 MICs for GBS COH1
and UPEC CFT073 were 72 g/ml (16 M) and 36 g/ml (8 M), respectively, while
CRAMP MICs were 72 g/ml and 288 g/ml (64 M), respectively (Fig. 1A and B). Similar
reductions in viable CFU counts were seen when GBS strains COH1, A909 (serotype Ia),
and NCTC 10/84 (serotype V) were incubated with 36 g/ml LL-37 in a 4-h kinetic killing
assay (Fig. 1C). In contrast to results obtained in RPMI 1640 medium, GBS exposed to
cathelicidin in synthetic urine was much more resistant to killing; the LL-37 MIC
increased to 288 g/ml for GBS COH1, with no growth inhibition of UPEC CFT073 at this
concentration. Murine CRAMP did not inhibit either GBS or UPEC in synthetic urine at
the highest concentration tested (288 g/ml) (Fig. 1D and E). To assess broad patterns
of GBS sensitivity to LL-37, 49 GBS clinical isolates from both colonizing (vaginal) and
invasive (skin, blood, and urine) sites were subjected to LL-37 MIC testing in RPMI 1640
medium. The most common MIC for GBS isolates was 72 g/ml (26 isolates), followed
by 36 g/ml (9 isolates) and 144 g/ml (8 isolates). Across body sites, no significant
differences in MICs were observed by a Kruskal-Wallis test (P 0.15) (Fig. 1F). Thus,
FIG 1 Susceptibility to cathelicidin is similar between UPEC and GBS clinical isolates. (A and B) MIC assays for COH1 and CFT073 using human LL-37 or murine
CRAMP) in RPMI 1640 medium. (C) Killing kinetics of three GBS strains by 36 g/ml (8 M) LL-37 in RPMI 1640 medium over time. (D and E) MIC assays for COH1
and CFT073 using human LL-37 or murine CRAMP in synthetic urine. Symbols represent the means of independent experimental replicates (n 3 to 5/group),
with lines indicating means and SEM. (F) MIC values of GBS clinical isolates collected from urine, vagina, skin, or blood. Symbols represent the means of three
independent experimental replicates (n 6 to 16/group). Data were analyzed by Kruskal-Wallis with Dunn’s multiple-comparison test. RFU, relative fluorescence
units.
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while GBS and UPEC are similarly sensitive to cathelicidin in cell culture medium that
reflects the ionic conditions of blood, conditions mimicking urine reduce cathelicidin
antimicrobial activity. Furthermore, these data do not indicate a selective pressure for
increased cathelicidin resistance among GBS urinary isolates compared to that of
isolates from other body sites.
GBS limits cathelicidin levels during bladder infection and exhibits cathelicidin
proteolytic activity. To investigate how GBS infection influences cathelicidin in blad-
der epithelium, the human bladder epithelial cell line HTB-9 was infected with GBS
strain A909, COH1, or NCTC 10/84 for 4 h at a multiplicity of infection (MOI) of 10 (10
bacteria to 1 host cell). Cells were lysed, and total LL-37 was quantified by enzyme-
linked immunosorbent assay (ELISA). Interestingly, HTB-9 cells generated less LL-37
when infected with GBS strain A909 (mean, 7.8 ng/ml; P 0.042), COH1 (mean, 9.5 ng/
ml; P 0.18), or NCTC 10/84 (mean, 5.7 ng/ml; P 0.0024) than the uninfected controls
(mean, 15.7 ng/ml) (Fig. 2A). This reduction in LL-37 production was not restricted to
GBS infection as HTB-9 cells infected with CFT073 for 4 h at an MOI of 10 also displayed
lower LL-37 levels (mean, 2.2 ng/ml; P 0.0016) than COH1-infected (7.2 ng/ml) and
uninfected controls (15.6 ng/ml) (Fig. 2B). To assess whether GBS infection impacted
LL-37 transcription, HTB-9 cells were infected with COH1 for 3 h at an MOI of 10 or 1,
and mRNA was quantified by quantitative PCR (qPCR) using glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as a housekeeping gene. No significant differences
were observed in LL-37 transcripts infected with GBS compared to results in uninfected
FIG 2 GBS infection limits bladder epithelium cathelicidin production, and GBS proteases degrade cathelicidin. (A and B) Human bladder
epithelial cells (HTB-9) were infected with GBS A909, COH1, or NCTC 10/84 or with GBS COH1 and UPEC CFT073, as indicated, for 4 h at
an MOI of 10. LL-37 production was measured by ELISA. (C) HTB-9 cells were infected with GBS COH1 for 3 h at an MOI of 10 or 1. LL-37
mRNA transcripts were quantified by qPCR and normalized to the level of the housekeeping gene, GAPDH, using the ΔΔCT method.
Symbols represent the means of independent experimental replicates (n 3 to 6/group), with lines indicating medians and interquartile
ranges. (D) GBS strains A909, COH1, and NCTC 10/84 were incubated with 9 g/ml (2 M) LL-37 for 4 h with or without addition of
protease inhibitors (PI). Samples were spotted onto a nitrocellulose membrane and probed for LL-37. Densitometry was normalized to the
signal from the 9-g/ml LL-37 input. Raw images of dot blots are depicted in Fig. S1 in the supplemental material. (E) Susceptibility of
GBS COH1 to 27 g/ml (6 M) LL-37 with or without protease inhibitors (PI) was measured over 4 h by serial dilution and plating. Symbols
represent the means of three independent experiments, and lines indicate the mean values of experimental replicates. (F) MIC assay of
GBS COH1 using human LL-37 in RPMI 1640 medium with (white bars) or without (gray bars) addition of protease inhibitors. Symbols
represent the means of independent experimental replicates (n 5/group), with lines indicating means and SEM. (G) Human bladder
epithelial cells (HTB-9) were infected with GBS COH1 and UPEC CFT073 for 4 h at an MOI of 10 with or without addition of protease
inhibitors. LL-37 production was measured by ELISA. Symbols represent the means of independent experimental replicates (n 6 to
8/group), with lines indicating medians and interquartile ranges. Data were analyzed by Friedman’s test with Dunn’s multiple-comparison
test (panels A to C), two-way repeated-measures ANOVA with Dunnett’s multiple-comparison test (panel E), or two-way ANOVA with
Sidak’s multiple-comparison test (panels D and G). ****, P 0.0001; **, P 0.01; *, P 0.05.
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controls (Fig. 2C). We used a lactate dehydrogenase (LDH) release assay to examine the
impact of GBS and UPEC infection on HTB-9 cell viability, with data normalized to 1%
Triton-X treatment (assumed 100% lysis). At an MOI of 1, toxicity was fairly low (20%
lysis) for all strains except GBS NCTC 10/84 (70% lysis), a hyperhemolytic strain (see
Fig. S1 in the supplemental material) (62). At an MOI of 10, GBS strains A909 and NCTC
10/84 both exhibited high toxicity (70% lysis), whereas CFT073 showed moderate
toxicity (24% lysis), and GBS COH1 showed minimal toxicity (5% lysis) (Fig. S1).
Cathelicidin is a target of degradation by bacterial proteases, as shown for Pseu-
domonas aeruginosa, Enterococcus faecalis, Proteus mirabilis, group A Streptococcus, and
enteropathogenic E. coli (63–65). To determine if GBS degradation of cathelicidin was
occurring, GBS strains A909, COH1, and NCTC 10/84 were incubated with 9 g/ml
(2 M, sub-MIC level) of LL-37 for 4 h with or without the addition of a protease
inhibitor (PI) cocktail. Dot blot analysis revealed degradation of LL-37 across GBS strains,
with a partial rescue of LL-37 levels in the presence of a protease inhibitors (Fig. 2D,
densitometry analysis; see uncropped blots in Fig. S2A to C). Similar degradation of
murine CRAMP was observed across GBS strains (Fig. S2D). Addition of a protease
inhibitor in the presence of 27 g/ml (6 M) LL-37 significantly reduced COH1 survival
at 4 h (mean, 4.3e8 CFU/ml; P  0.0001) compared to that of LL-37-treated COH1 cells
without protease inhibitors (7.4e7 CFU/ml) (Fig. 2E). Additionally, protease inhibition
reduced the LL-37 MIC from 72 g/ml to 18 g/ml (4 M) (Fig. 2F). Protease activity
alone did not fully account for the reduction of LL-37 in GBS- and UPEC-infected cells
as protease inhibitor treatment did not significantly rescue LL-37 production during
infection with COH1 (mean, 5.9 ng/ml for COH1 with PI; mean 4.6 ng/ml COH1 infection
alone) or CFT073 (mean, 3.1 ng/ml CFT073 with PI; mean, 5.3 ng/ml for CFT073 infection
alone) compared to that in uninfected controls (PI treatment mean, 1.3 ng/ml; no-
treatment mean, 13.0 ng/ml) (Fig. 2G). Specific protease inhibitors for serine, cysteine,
aspartyl, and aminopeptidase proteases were also added to GBS cultures with or
without 27 g/ml LL-37; no single protease inhibitor achieved the level of reduced GBS
survival equal to that of the protease inhibitor cocktail (Fig. S3).
Cathelicidin deficiency reduces GBS burden in the bladder. Since cathelicidin
itself is a biomarker for UTI (47), we studied its production during UTI in a murine
model. WT C57BL/6 female mice were infected with GBS COH1 or UPEC CFT073 or mock
infected with phosphate-buffered saline (PBS). Bladders were collected at 24 h postin-
fection, and cathelicidin was quantified by ELISA. Mice infected with UPEC CFT073 had
robust induction of cathelicidin (median, 1,756 ng/g; P 0.0001) compared to that of
mock-infected controls (median, 220 ng/g), whereas mice infected with GBS lacked this
robust increase (median, 327 ng/g; P 0.48) (Fig. 3A). To test the biological relevance
of cathelicidin during GBS UTI, WT and cathelicidin-deficient Camp/ mice were
infected with GBS COH1, and bladders and kidneys were collected at 24 h postinfection.
Surprisingly, Camp/ mice displayed lower GBS burdens (median, 1.63e4 CFU/g;
P 0.026) in the bladder than WT mice (median, 1.82e5 CFU/g) (Fig. 3B). No significant
differences in burdens were observed in the kidneys between WT and Camp/ mice
(median, 9.76e4 CFU/g and not detected, respectively; P 0.69).
To determine if this phenotype correlated with an acute deficiency of cathelicidin
during infection, rather than a sustained effect of cathelicidin knockout (KO) on bladder
and/or immune development and maturation, WT and Camp/ mice were instilled
with a single intravesicular dose of recombinant CRAMP (rCRAMP; 320 M) 1 h prior to
GBS infection. At 24 h postinfection, pretreatment with rCRAMP resolved differences in
bladder burdens between WT and Camp/ mice (median, 4.41e5 CFU/g and 5.47e5
CFU/g, respectively; P 0.96), whereas untreated mice recapitulated differences seen in
the data shown in Fig. 3B (median, 4.12e5 CFU/g and 1.35e4 CFU/g, respectively;
P 0.0071) (Fig. 3C). Treatment with rCRAMP did not significantly increase GBS bladder
burdens over the levels in mock-treated mice. Additionally, no significant differences
were observed in kidney burdens across genotypes and treatment groups (Fig. 3C).
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To assess the contribution of cathelicidin to GBS-host interactions in additional
relevant models, we utilized murine models of vaginal colonization and sepsis. No
differences in GBS persistence were observed during vaginal colonization between WT
and Camp/ mice (Fig. 3D). Furthermore, in a sepsis model of GBS, Camp/ mice
displayed a modest increase in blood bacterial load compared to that of WT mice (2.0e7
CFU/ml and 6.0e6 CFU/ml, respectively; P 0.035) but no differences in spleen or
kidney burdens (Fig. 3E). Together, these data suggest that the enhanced resistance of
Camp/ mice to GBS in the bladder is specific to UTI and the bladder microenviron-
ment.
Cathelicidin deficiency alters bladder immune cell populations in response to
GBS. Based on the observations of poor antimicrobial activity of cathelicidin in urine
and lower GBS burdens in Camp/ mice, we characterized the immune cell profiles of
WT and Camp/ mice during GBS UTI using flow cytometry. Bladder cells were
collected from WT and Camp/ mice at 24 h postinfection with GBS and stained with
antibodies for the following cell surface markers: CD45, CD11b, CD11c, majory histo-
compatibility complex class II (MHC-II), Ly6C, Ly6G, FcRI, and c-kit. See Fig. S4 for the
gating strategy. Similar to previous findings on immune cell populations in the bladder
during UPEC infection (31, 66), dominant CD45 populations 24 h postinfection
consisted of neutrophils (CD11b CD11c/ Ly6G), macrophages/NK cells (CD11b
CD11c/ Ly6C Ly6G), monocytes (CD11b CD11c/ Ly6C), mast cells (c-kit
FcRI), and antigen-presenting cells (CD11c MHC-II) (/ annotation indicates cells
in that category may be either positive or negative for staining of CD11c). While no
differences were seen in immune cell populations in mock-infected animals, infected
WT mice displayed higher mast cell percentages than Camp/ mice (median, 10.6%
FIG 3 Cathelicidin deficiency reduces GBS burden in the bladder. (A) WT C57BL/6 female mice were transurethrally infected with 2 107 CFU
of GBS COH1 or UPEC CFT073 or mock infected as a control. Bladders were collected at 24 h postinfection, and cathelicidin levels were quantified
by ELISA. (B) WT C57BL/6 and Camp/ female mice, as indicated, were transurethrally infected with 2 107 CFU of GBS COH1. Bladders and
kidneys were collected at 24 h postinfection to determine GBS burdens. (C) WT C57BL/6 and Camp/ mice were infected with GBS COH1 as
described for panel B, with the inclusion of recombinant CRAMP treatment (320 M) transurethrally 1 h prior to infection or mock treatment with
PBS as a control. Bladders and kidneys were collected at 24 h postinfection to determine GBS burdens. (D) WT C57BL/6 and Camp/ female mice
were vaginally administered 2 107 CFU of GBS COH1. Mice were vaginally swabbed daily, and the levels of GBS CFU recovered from swabs are
shown. (E) WT C57BL/6 and Camp/ male mice were injected i.p. with 2 107 CFU of GBS COH1. Blood, spleen, and kidneys were collected at
24 h postinfection to determine GBS burdens. Experiments were conducted at least two times independently, and data were combined. Symbols
represent biological replicates (n 8 to 32/group), with lines indicating medians with interquartile ranges. Dotted lines indicate limits of detection
for CFU. Data were analyzed using Kruskal-Wallis with Dunn’s multiple-comparison test (panel A) or two-way repeated measures ANOVA with
Sidak’s multiple-comparison test (panels B to E). ****, P 0.0001; **, P 0.01; *, P 0.05.
Patras et al.
March/April 2020 Volume 5 Issue 2 e00932-19 msphere.asm.org 6
and 2.0% of CD45, respectively; P 0.021). Furthermore, infected Camp/ mice
exhibited higher percentages of neutrophils than infected WT mice (median, 18.9% and
8.7% of CD45, respectively; P 0.0046) (Fig. 4A). While total CD45 cells increased in
WT infected mice compared to the level in mock-infected mice, there was no significant
increase in the level in Camp/-infected mice over that in mock-infected mice
(Fig. 4B). Importantly, WT infected mice displayed significantly more mast cells than
Camp/mice (median, 4,014 cells and 1,038 cells per bladder, respectively; P 0.032),
but no significant increase in neutrophil counts was observed (Fig. 4C).
Mast cells are highly granulated innate immune cells that serve multiple functions,
including surveillance of pathogens through Toll-like receptor (TLR) signaling, proin-
flammation via histamine release, and direct bacterial killing through cathelicidin and
protease release (67). Similarly, neutrophils are vital to antibacterial defense of the
bladder, as demonstrated through multiple neutrophil depletion studies (32, 68, 69). To
corroborate flow cytometry counts, bladders from GBS-infected and mock-infected WT
and Camp/ mice were collected at 24 h postinfection and subjected to ELISA for
histamine and neutrophil myeloperoxidase (MPO). WT infected mice exhibited in-
creased levels of histamine compared to those in Camp/ infected mice (me-
dian, 1,484 ng/g and 1,031 ng/g, respectively; P 0.0078) (Fig. 4D). In infected animals,
MPO levels were increased in Camp/ mice over levels in WT mice (median, 89.2 ng/g
and 45.2 ng/g, respectively; P 0.0020) (Fig. 4E). No differences in either histamine or
MPO levels between mock-infected WT and Camp/ mice were observed.
Mast cell inhibitor cromolyn sodium reduces GBS burden in the bladder.
Because WT mice infected with GBS COH1 displayed both increased bacterial burdens
and mast cell numbers in the bladder at 24 h postinfection, we next assessed if mast
FIG 4 Cathelicidin deficiency alters bladder immune cell populations in response to GBS. WT C57BL/6 and Camp/ female mice were transurethrally infected
with 2 107 CFU of GBS COH1 or mock infected as a control. Bladders were collected at 24 h postinfection and analyzed via flow cytometry The gating strategy
of CD45 lymphocytes is described in Fig. S4 in the supplemental material. (A) Percentage of CD45 cells staining for given surface markers. (B) Total counts
of CD45 cells from mouse bladders. (C) Total counts of cells from panel B which stained for given surface markers. Bladders were also subjected to histamine
(D) and myeloperoxidase (MPO) ELISA (E). Experiments were conducted at least two times independently, and data were combined. Symbols represent
biological replicates (n 4 to 33/group), with lines indicating medians with interquartile ranges. Data were analyzed using two-way repeated-measures ANOVA
with Tukey’s multiple-comparison test (panels A and C), Kruskal-Wallis with Dunn’s multiple-comparison test (panel B), and one-way ANOVA with Holm-Sidak’s
multiple-comparison test (panels D and E). Significant differences are shown. All other comparisons are not significant (P 0.05). ***, P 0.001; **, P 0.01;
*, P 0.05.
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cell inhibition might improve host outcomes during GBS UTI. Mast cell degranulation
can be pharmacologically inhibited using the FDA-approved drug cromolyn sodium,
previously shown to be efficacious in reducing bladder inflammation in mice (70). WT
and Camp/ mice were treated with 10 mg/kg of cromolyn sodium injected intra-
peritoneally (i.p.) at 48 h, 24 h, and 1 h prior to bladder infection with COH1. WT mice
receiving cromolyn exhibited a significant reduction in GBS bladder burden at 24 h
postinfection compared to levels in mock-treated WT mice (median, 2.01e4 CFU/g and
2.47e5 CFU/g, respectively; P 0.043) (Fig. 5A). Camp/ mice receiving cromolyn had
GBS burdens similar to those of mock-treated Camp/mice (6.21e4 CFU/g and 2.09e4
CFU/g, respectively; P 0.12). As seen in Fig. 3B and C, mock-treated WT mice had
significantly higher GBS burdens than mock-treated Camp/ mice (P 0.0078). No
significant differences in kidneys of GBS-infected mice were observed among all groups
(Fig. 5A). To determine whether cromolyn treatment reduced mast cell degranulation
in the bladders of WT mice, bladder homogenates were subjected to ELISA for
histamine and neutrophil myeloperoxidase (MPO). Cromolyn treatment significantly
reduced histamine levels in WT mice compared to levels in mock-treated WT mice
(median, 905 ng/g and 1,292 ng/g, respectively; P 0.0015) (Fig. 5B) whereas cromolyn
treatment did not alter histamine levels in Camp/ mice (961 ng/g and 877 ng/g,
respectively; P 0.99). As seen in the data of Fig. 4D, WT mock-treated mice displayed
higher histamine levels than mock-treated Camp/ mice (P 0.0009) and cromolyn-
treated Camp/ mice (P 0.042). Conversely, cromolyn treatment did not impact
levels of MPO in WT mice (median, 67.9 ng/g in cromolyn-treated mice and 39.1 ng/g in
mock-treated mice; P 0.5057) (Fig. 5C). Similar to the data shown in Fig. 4E, both
mock-treated Camp/ (median, 95.5 ng/g) and cromolyn-treated Camp/ (me-
dian, 89.2 ng/g) mice had higher MPO levels than WT mice (P 0.0033 and P 0.0044,
respectively) (Fig. 5C).
Since mast cells are protective in a variety of Gram-positive and Gram-negative
bacterial infections (71), we tested whether mast cells controlled and/or killed GBS in
vitro. The human mast cell line HMC-1 was infected with GBS COH1 at an MOI of 0.1 for
60 min, and total counts of recovered bacteria were determined by serial dilution and
plating. HMC-1 cells failed to control GBS growth (median recovered CFU
amount, 122% of inoculum) (Fig. S5A). Furthermore, a 30-min pretreatment of HMC-1
with 100 M cromolyn sodium (72), physiologic levels of LL-37 (288 ng/ml), or both
cromolyn and LL-37 combined did not alter the amount of GBS CFU recovered
(Fig. S5A). Similarly, HMC-1 cells infected with UPEC CFT073 failed to demonstrate
potent bacterial killing (median recovered CFU amount, 98.4% of inoculum) (Fig. S5B),
FIG 5 Mast cell inhibitor cromolyn sodium reduces GBS burden in the bladder. WT C57BL/6 and Camp/ female mice were treated with
the mast cell membrane stabilizer cromolyn sodium at 10 mg/kg/dose at 48 h, 24 h, and 1 h prior to transurethral infection with 2 107
CFU of GBS COH1. Mock-treated mice were used as controls. Bladder and kidneys were collected at 24 h postinfection to determine
bacterial burdens (A). Bladders were also subjected to histamine (B) and myeloperoxidase (MPO) ELISA (C). Experiments were conducted
at least two times independently, and data were combined. Symbols represent biological replicates (n 10 to 18/group), with lines
indicating medians with interquartile ranges. Data were analyzed using two-way repeated-measures ANOVA with Tukey’s multiple-
comparison test (panel A) and one-way ANOVA with Tukey’s multiple-comparison test (panels B and C). ***, P 0.001; **, P 0.01; *,
P 0.05.
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nor did cromolyn sodium or LL-37 treatment alter amounts of UPEC CFU recovered
(Fig. S5B).
STZ-induced diabetes increases susceptibility to GBS UTI. Patients with type 2
diabetes or gestational diabetes are more susceptible to GBS invasive disease, including
UTI and soft tissue infections (12, 13, 21), but the host factors contributing to GBS
susceptibility are not well described. To investigate if an animal model of diabetes can
recapitulate the enhanced GBS susceptibility observed in the human population, we
utilized an inducible murine model of diabetes using the compound streptozotocin
(STZ) (73). WT CD1 female mice received daily doses of 80 mg/kg STZ i.p. for 4 days or
were mock treated as controls beginning 20 to 22 days prior to infection. At 1 week
posttreatment, body weights were similar between STZ-treated and control mice
(mean, 36.5 g versus 36.7g; P 0.99) (Fig. 6A). STZ-treated mice exhibited moderate
weight loss approximately 2 weeks posttreatment (34.5 g versus 38.7 g; P 0.0054);
however, weight loss was stabilized by 1 day prior to GBS infection (34.6 g versus 40.6
g; P 0.0001). Additionally, STZ-treated mice were hyperglycemic (mean, 393 mg/dl in
STZ-treated mice versus 142 mg/dl in controls; P 0.0001) (Fig. 6B), with glucosuria
(mean, 478 mg/dl in STZ-treated mice versus 96.5 mg/dl in controls; P 0.0001)
(Fig. 6C) 24 h prior to infection. Mice were transurethrally infected with 2 107 CFU
GBS COH1, and at 24 h postinfection, urine, bladder, and kidneys were collected.
STZ-treated mice had significantly higher GBS burdens in the urine than mock-treated
control mice (median, 1.04e5 CFU/ml and 5.60e3 CFU/ml, respectively; P 0.046) and
bladder (median, 1.33e2 CFU/organ and 1.5e2 CFU/organ, respectively; P 0.0057)
(Fig. 6D). No significant differences were observed in the kidneys of STZ-treated and
control mice (median, 1.87e2 CFU/organ and 1.41e4 CFU/organ, respectively; P 0.88).
To examine whether differences in bacterial burdens in STZ-treated mice impacted
bladder immune cell populations, we performed flow cytometry of bladders at 24 h
postinfection. STZ-treated mice showed no changes to infiltrating neutrophils (CD11b
Ly6C Ly6G) and monocytes (CD11b Ly6C Ly6G) (Fig. 6E). However, STZ-treated
FIG 6 Streptozotocin-induced diabetes increases susceptibility to GBS UTI. WT CD1 female mice were treated with 4 doses of 80/mg/kg/dose streptozotocin
(STZ) as described in Materials and Methods. Mock-treated mice were used as controls. At 3 weeks following treatment, mice were transurethrally infected with
2 107 CFU of GBS COH1. (A) Body weights were collected weekly following STZ treatment. (B) Blood glucose at 24 h prior to infection. (C) Urine glucose
collected at 24 h postinfection. (D) Urine, bladder, and kidneys were collected at 24 h postinfection to determine bacterial burdens. (E) Bladders collected at
24 h postinfection were analyzed via flow cytometry. The gating strategy is described in Fig. S4 in the supplemental material. (F) Bladder weights of mice at
24 h postinfection. Bladders were subjected to cathelicidin ELISA (G) and histamine ELISA (H). Experiments were conducted at least two times independently,
and data were combined. Symbols represent biological replicates (n 10 to 30/group), with lines indicating medians with interquartile ranges. Dotted lines
indicate upper limits of detection for glucose meter (panels B and C) and lower limits of detection for CFU (panel D) or ELISA (panels G and H). Data were
analyzed by two-way repeated-measures ANOVA with Sidak’s multiple-comparison test (panels A, D, and E) and a two-tailed Mann-Whitney test (panels B, C,
and F to H). ****, P 0.0001; ***, P 0.001; **, P 0.01; *, P 0.05; n.s., not significant.
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mice displayed significantly higher populations of mast cells (c-kit FcRI) than
control mice (1.75e4 cells/bladder and 3.51e3 cells/bladder, respectively; P 0.0001)
(Fig. 6E). Additionally, significantly higher numbers of CD11b Ly6C Ly6G cells were
observed in STZ-treated mice than in control mice (4.58e4 cells/bladder and 1.05e4
cells/bladder, respectively; P 0.0001) (Fig. 6E). Because bladder weights of STZ-
treated mice (median, 0.0376 g) were higher than those of control mice (median, 0.0237
g; P 0.0002) (Fig. 6F), cathelicidin and histamine levels, measured by ELISA, were
compared as total amounts detected per bladder. Bladder levels of cathelicidin were
significantly higher in STZ-treated mice (median, 14.7 ng/bladder) than in control mice
(median, 5.9 ng/bladder; P 0.030) (Fig. 6G). However, no differences were observed in
histamine levels between STZ-treated mice (median, 13.9 ng/bladder) and control mice
(median, 19.6 ng/bladder; P 0.053) (Fig. 6H).
Nonetheless, given the higher numbers of mast cells observed in STZ-treated mice
(Fig. 6E), we examined whether the mast cell inhibitor cromolyn sodium would impact
control of GBS burdens. Interestingly, although cromolyn sodium treatment did not
significantly reduce GBS burdens in STZ-treated mice (P 0.0584), cromolyn sodium
treatment resolved differences between control mice and STZ-treated mice (Fig. 7A).
Additionally, STZ-treated mice given cromolyn sodium, unlike the mock-treated STZ-
treated mice, did not show significantly higher cathelicidin levels (Fig. 7B). No signifi-
cant changes in histamine levels were observed across groups (Fig. 7C). To examine
whether cathelicidin deficiency was still protective in diabetes, WT and Camp/ mice
were treated with STZ and infected with GBS, and bladder burdens were compared to
those of nondiabetic mice (values from the experiment shown in Fig. 3B). WT mice
treated with STZ demonstrated higher GBS burdens per bladder than nondiabetic WT
mice (median, 3,800 CFU and 1,800 CFU, respectively; P 0.13), nondiabetic Camp/
mice (median, 200 CFU; P 0.018), and diabetic Camp/ mice (median, 260 CFU;
P 0.15). Conversely, GBS burdens in bladders of STZ-treated Camp/ mice were
similar to those of nondiabetic Camp/ mice (P 0.71) (Fig. 7D). Together, these
findings support a model in which cathelicidin production in diabetic UTI correlates
with an ineffective immune response and in which pharmacologic inhibition of mast
cells may enhance host control of GBS.
DISCUSSION
Individuals with dysfunctional metabolisms, such as those with type 2 diabetes and
gestational diabetes, are at increased risk for UTI, with GBS disproportionately repre-
sented as a causative agent compared to causes of UTI in otherwise healthy individuals
(10). Here, we investigated the antimicrobial peptide cathelicidin in host defense
FIG 7 Impact of cromolyn sodium treatment and CRAMP deficiency in STZ-induced diabetic mice. WT CD1 female mice were treated with streptozotocin (STZ)
and/or cromolyn sodium and infected with 2 107 CFU of GBS COH1 as described in Materials and Methods. (A) Bladder and kidneys were collected at 24 h
postinfection to determine bacterial burdens. Bladders were subjected to cathelicidin ELISA (B) and histamine ELISA (C). (D) WT C57BL/6 and Camp/ female
mice were treated with STZ and infected with 2 107 CFU of GBS COH1 as described in Materials and Methods, with bladders collected 24 h postinfection.
Mock-treated animals from the experiments shown in Fig. 3B are shown for comparison. Experiments were conducted one to two times independently, and
data were combined where appropriate. Symbols represent biological replicates (n 8 to 25/group), with lines indicating medians with interquartile ranges.
Dotted lines indicate lower limits of detection for CFU (panels A and D) or ELISA (panels B and C). Data were analyzed using two-way repeated-measures ANOVA
with Tukey’s multiple-comparison test (panel A) and one-way ANOVA with Tukey’s multiple-comparison test (panels B to D). *, P 0.05; n.s., not significant.
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against GBS UTI. Unexpectedly and in contrast to a protective role in UPEC UTI (46), we
found that cathelicidin aggravates GBS UTI in a manner dependent on mast cell
degranulation. We propose that cathelicidin is an important immune regulator but
ineffective antimicrobial peptide against GBS in urine, which may in part explain the
increased frequency of GBS UTI in diabetic and pregnant individuals.
Although cathelicidin protects the urinary tract against UPEC infection, presumably
through antimicrobial activity (46), we failed to detect antimicrobial activity of LL-37 or
CRAMP against UPEC in synthetic urine at concentrations up to 288 g/ml (Fig. 1).
Similarly, we observed a loss of antimicrobial activity toward GBS in synthetic urine.
Modest increased bacterial resistance to LL-37 and CRAMP has been previously re-
ported under high-salt conditions (58, 74), and this may be one factor contributing to
the loss of antimicrobial activity in urine. We observed that 27% (13/49) of GBS clinical
isolates showed resistance to cathelicidin killing at a concentration of 32 M or higher
in tissue culture medium (Fig. 1), a level of resistance observed previously among GBS
strains (75, 76). Additionally, we did not observe selective pressure for cathelicidin
resistance in GBS urinary isolates, in contrast to previous observations with UPEC
pyelonephritis isolates (46). Even so, the range of susceptibilities of GBS clinical isolates
was similar to that previously reported for UPEC cystitis and pyelonephritis isolates (30
to 60 M) (46). Similar to our findings with GBS, CRAMP-deficient mice were recently
found to be more resistant to a UPEC cystitis isolate (48); however, unlike infection of
Camp/ mice with GBS (Fig. 4), CRAMP deficiency in UPEC infection coincided with
attenuated immune cell recruitment and decreased tissue damage. Collectively, these
data support a more complex role for cathelicidins in the urinary tract beyond antimi-
crobial mechanisms.
Probing the reduction of LL-37 in GBS-infected bladder epithelial cells, we found
that multiple GBS strains could degrade LL-37 in a protease-dependent manner and
that GBS is further sensitized to LL-37 with the addition of protease inhibitors (Fig. 2).
Proteolysis of cathelicidins has been reported by serine proteases, cysteine proteases,
and metalloproteases from human-pathogenic bacteria (77–79), but testing with spe-
cific protease inhibitors did not allow us to pinpoint the type(s) of GBS protease
responsible for this degradation (see Fig. S3 in the supplemental material). Of note,
addition of protease inhibitors to bladder epithelial cells infected with either GBS or
UPEC was not sufficient to rescue production of LL-37 compared to levels in uninfected
cells (Fig. 2F). This observation is in line with reports by Chromek et al. (46), which
demonstrated an initial surge in cathelicidin transcripts during UPEC infection but not
later time points, suggesting that cell stress may be a factor limiting production of
LL-37. Additionally, the HTB-9 bladder cell line was isolated from a grade II carcinoma
and may not accurately reflect responses of the healthy or diabetic bladder epithelium.
Whether cathelicidin is an effective antimicrobial defense against GBS remains
unclear, and its activity may be tissue dependent. In this study, addition of a single dose
of rCRAMP 1 h prior to infection (72 g), which was well above endogenous levels of
CRAMP in UPEC-infected mice (maximum level detected, 150 ng/bladder), did not
reduce GBS bladder burdens in WT or Camp/ mice (Fig. 3). In bovine mastitis,
cathelicidin is strongly induced, particularly when GBS is the causative agent (80). In the
reproductive tract, cathelicidin levels rise during pregnancy (81), but the amount of
cathelicidin is insufficient to kill GBS (82). This observation is corroborated in our murine
model as cathelicidin deficiency did not impact GBS vaginal colonization (Fig. 3D);
however, we did not examine colonization beyond 4 days, so the possibility of a
delayed phenotype cannot be ruled out. During sepsis, cathelicidin may confer partial
protection in controlling GBS burden in the bloodstream though other organs, such as
the spleen and kidneys, were not impacted by cathelicidin deficiency in our experi-
ments. In the bladder, mice did not show robust induction of cathelicidin upon GBS
infection, particularly compared with levels in UPEC-infected mice (Fig. 3A), but it is
currently unknown whether this same phenomenon occurs in humans during GBS UTI.
In one study, elevated plasma and urinary LL-37 levels were observed in patients with
UTI; however, GBS was not a causative UTI agent in this particular cohort (47).
Cathelicidin Exacerbates GBS UTI
March/April 2020 Volume 5 Issue 2 e00932-19 msphere.asm.org 11
Alternatively, it is possible that GBS actively suppresses cathelicidin production in the
urogenital tract. In placental specimens, significantly lower cathelicidin placental levels
were observed in GBS-positive women (83). However, in this study, we saw no evidence
of alterations to bladder LL-37 transcription during GBS infection in vitro (Fig. 2C).
Cathelicidins are increasingly appreciated as immunomodulatory peptides that can
activate or suppress inflammation and exert chemotactic effects on a variety of immune
cells (84). Epithelial, resident, and invading innate immune cells can serve as sources for
cathelicidin during infection (84). When we analyzed the immune profiles of
cathelicidin-deficient mice in response to GBS UTI, we found a selective reduction in
mast cell recruitment and degranulation (Fig. 4). Similarly, human LL-37 induces mast
cell chemotaxis and degranulation and increases mast cell expression of TLR4 (85–87).
Mast cell activation by LL-37 is thought to act through the MrgX2 receptor, a G
protein-coupled receptor (GPCR), but other receptors, including FPRL1 and P2X7, have
been proposed (88). The proinflammatory functions of cathelicidin have been observed
in many human diseases and mouse inflammatory models (51, 89–92), and this capacity
to enhance tissue inflammation is consistent with the observations in our study.
Interestingly, in the absence of cathelicidin, we saw an enhancement of neutrophil MPO
release (Fig. 4), which may explain the reduction in GBS CFU levels compared to those
of WT mice, but the molecular factors promoting this neutrophil response are beyond
the scope of this study.
Mast cells have been implicated in the host defense against numerous bacterial
pathogens. In addition to supporting neutrophil and macrophage antimicrobial prop-
erties, mast cells themselves possess mechanisms to directly kill bacteria, including
release of proteases, extracellular traps, and antimicrobial peptides, including catheli-
cidins (71, 93, 94). In the context of UPEC UTI, mast cells provide host protection. UPEC
infection drives mast cell recruitment to the bladder and stimulates histamine release
via FimH (34). Additionally, interleukin-1 (IL-1) and/or inflammasome activation
triggers mast cell recruitment to UPEC UTI, as caspase-1/11 KO mice are deficient in
mast cell bladder recruitment (95). To complement mast cell-mediated inflammation,
mast cells are the predominant producers of IL-10, suggesting dual roles of mast cells
in initiating and resolving bladder inflammation (96). Mast cells and their associated
proteases play a role in host protection against GBS in systemic and intrauterine
infection (97) and in the context of vaginal colonization (98). GBS stimulates mast cell
degranulation (98), but neither a prior study (98) nor this work (Fig. S5A) could
demonstrate direct killing of GBS by the mast cell line HMC-1. It has been noted that
this cell line is deficient in tryptase and chymase activity compared to the levels in
mature human skin mast cells (99). Moreover, the contribution of mast cells to GBS UTI
was not assessed using mast cell-deficient animals, which is a limitation of this study.
Diabetes mellitus and gestational diabetes are widely recognized risk factors for UTI
(100, 101), including UTI caused by GBS (102, 103); however, the host immune defi-
ciencies explaining this phenomenon are poorly understood. For instance, neutrophils
from type 2 diabetics are equally as capable of GBS phagocytosis as those of healthy
counterparts (104). Here, we introduce for the first time a murine diabetic model to
study GBS UTI using multiple doses of streptozotocin (STZ) to induce necrosis of
pancreatic beta cells (105). STZ-treated mice are more susceptible to UPEC UTI, in part
through enhanced bacterial adherence (73). Although STZ treatment results in a model
more like type 1 diabetes, similarities exist, including excessive glucosuria (Fig. 6).
Recent reports of spontaneous GBS soft tissue infections in a type 2 diabetic genetic
mouse model suggest that increased GBS susceptibility is maintained across multiple
diabetic manifestations (106).
We found that STZ-treated mouse bladders had more GBS CFU, higher cathelicidin
levels, and more infiltrating immune cells, making it difficult to distinguish immune
populations impacted by host metabolic dysfunction and elevated responses to in-
creased bacterial burdens. From these data, we cannot differentiate the source of
cathelicidin in STZ-treated mice since bladder epithelial cells, as well as mast cells,
neutrophils, and other myeloid lineage cells (which were increased in STZ-treated
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mice), are all known to produce cathelicidin. Higher cathelicidin in diabetes has been
identified at inflamed mucosal cites (55), in the kidneys during acidosis (107), and in
infected macrophages (108). Additionally, GBS burdens were no different between
diabetic and nondiabetic Camp/ mice in our model (Fig. 7). Together, these studies
implicate a detrimental impact of cathelicidin in control of GBS UTI in diabetes.
In both our genetic model of cathelicidin deficiency and the diabetic mouse model,
increased bladder mast cells corresponded with higher GBS burdens. Mast cell degran-
ulation promotes bladder epithelial cell shedding (95), and we speculate that this tissue
damage response may enhance GBS adherence or invasion of the bladder. Cromolyn
sodium reduces inflammation and reverses lower urinary tract dysfunction in a murine
model of autoimmune cystitis (70) but, to our knowledge, has not been investigated in
the context of UTI. Cromolyn sodium-mediated reduction of neutrophil chemotaxis and
generation of oxygen radicals have been reported (109, 110). Although we did not
observe changes in neutrophil myeloperoxidase in response to cromolyn sodium
(Fig. 5C), involvement of other myeloid cells besides mast cells in explaining a reduction
of GBS CFU levels in cromolyn-treated mice cannot be ruled out in this study. Our
results using cromolyn sodium compellingly support the idea that inhibition of mast
cells enhances host control of GBS in the bladder (Fig. 5 and 6). Cromolyn treatment
lowered histamine levels and bacterial burdens in our GBS model in C57BL/6 mice
(Fig. 5). However, in a CD1 mouse background, cromolyn sodium treatment did not
alter histamine levels but did resolve bacterial burden differences between diabetic and
nondiabetic animals (Fig. 7). These findings support a complex role for mast cells in
control of UTI. Immune responses supported by mast cell degranulation, including IL-6
and tumor necrosis factor alpha (TNF-), may impair neutrophil and macrophage
bacterial clearance of GBS, as recently observed in Streptococcus pneumoniae lung
infection (111), perhaps explaining why neutrophil MPO responses were higher in
Camp/ mice (Fig. 4).
In summary, we have highlighted cathelicidin as a potent immune regulator, rather
than an antimicrobial effector, in the bladder during GBS UTI, driving the recruitment
of mast cells. There is mounting evidence for the importance of mast cells in modu-
lating bladder function during both sterile and infection-mediated inflammation. In the
context of GBS UTI, mast cells may be detrimental in controlling infection, and mech-
anistic insight is a focus of future studies. These findings expand our knowledge of the
host factors contributing to GBS UTI and support cathelicidin and mast cell signaling
pathways as targets for controlling GBS UTI in susceptible populations.
MATERIALS AND METHODS
Bacterial strains, growth conditions, and MIC and growth curve testing. Group B Streptococcus
(GBS) strains used in this study include COH1 (ATCC BAA-1176), A909 (ATCC BAA-1138), and NCTC 10/84
(ATCC 49447) and wild-type GBS clinical isolates from adults obtained from Sharp Memorial Hospital, San
Diego, CA (IRB approval no. 1805802), which were grown for at least 16 h in stationary culture to
stationary phase at 37°C in Todd-Hewitt Broth (THB) prior to experiments. Clinical GBS isolates were
confirmed by growth as pink/mauve colonies on CHROMagar StrepB (catalog no. SB282; DRG Interna-
tional) as well as by the presence of the group B carbohydrate via latex bead agglutination (R30950701;
Remel Streptex). For killing kinetics and MIC assays, overnight cultures were diluted 1:10 in fresh THB and
incubated under stationary conditions at 37°C until mid-log phase (optical density at 600 nm [OD600] of
0.4).
Uropathogenic E. coli (UPEC) strain CFT073 (O6:K2:H1; ATCC 700928) was grown for at least 16 h in
shaking culture to stationary phase at 37°C in Luria-Bertani (LB) broth prior to experiments. For MIC
assays, overnight cultures were diluted 1:30 in fresh LB broth and incubated with shaking at 37°C until
mid-log phase (OD600 of 0.4).
For killing or growth kinetics, log-phase GBS cultures were diluted 1:30 in RPMI 1640 medium (Gibco)
in 96-well microtiter plates with or without 27 g/ml (6 M) or 36 g/ml (8 M) LL-37 (catalog no.
4042456; Bachem) in a 300-l total volume. To test the effect of protease activity on GBS survival, Halt
protease inhibitor cocktail (catalog no. PI78425, 1; ThermoFisher), serine protease inhibitor cocktail
(56-500-01VL, 1; Millipore), (Z-LL)2 ketone cysteine protease inhibitor (42-105-05MG, 5 M; Millipore),
pepstatin A aspartyl protease inhibitor (50-114-6412, 10 M; AdipoGen), and bestatin hydrochloride
aminopeptidase inhibitor (B8385-1MG, 50 M; Sigma-Aldrich) were added at the given concentrations.
Plates were incubated under stationary conditions for 4 h at 37°C. At 0, 1, 2, and 4 h, samples were serially
diluted and plated on THB agar. The number of CFU was determined and expressed as a percentage of
the CFU count at time zero.
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For MICs, mid-log-phase cultures were diluted 1:100 in synthetic urine (59) or RPMI 1640 medium
(Gibco) with or without LL-37 or CRAMP (catalog no. 4056438; Bachem) at concentrations ranging from
0 to 288 g/ml (0 to 64 M) in a 100-l total volume in 96-well microtiter plates. To test the effect of
protease activity on MIC, Halt protease inhibitor cocktail (100; ThermoFisher) was added at 1:100. Plates
were incubated under stationary conditions for 24 h at 37°C. To measure metabolic activity, resazurin
(Sigma-Aldrich) was added at 6.75 g g/ml, and plates were incubated at 37°C for 3 h. Fluorescence,
indicated by resazurin-to-resofurin conversion, was read at an excitation wavelength of 550 nm and
emission wavelength of 600 nm on an Enspire plate reader (Perkin-Elmer). The MIC was determined by
a 90% reduction in fluorescent signal from the conversion of resazurin to fluorescent resorufin.
Cell lines and infection assays. The human bladder epithelial cell line 5637 (ATCC HTB-9) was
cultured in RPMI 1640 medium (Gibco) supplemented with 10% heat-inactivated fetal bovine serum (FBS)
at 37°C in humidified air with 5% CO2. The human mast cell line HMC-1 (112) was cultured in Iscove’s
modified Dulbecco’s medium (IMDM) (catalog no. 21056-023; Gibco) supplemented with 1.2 mM
1-thioglycerol (M6145-100ML; Sigma-Aldrich) and 10% FBS at 37°C in humidified air with 5% CO2.
For LL-37 stimulation assays, HTB-9 cells were infected as described previously (44). Briefly, HTB-9
monolayers were grown in 24-well tissue culture plates to confluence. Fresh medium was added (400 l),
and cells were infected with log-phase GBS or UPEC in 100 l at a multiplicity of infection (MOI) of 10
or 1 (bacterium-to-cell ratio). Cells were incubated for 3 h (qPCR) or 4 h (ELISA) at 37°C with 5% CO2. For
transcript analyses, mRNA was extracted using a Purelink RNA minikit (ThermoFisher) per the manufac-
turer’s instructions. For protein analyses, cells were lysed with vigorous pipetting in radioimmunopre-
cipitation assay (RIPA) buffer and protease inhibitor cocktail, and samples were frozen at –20°C. Where
applicable, 1 Halt protease inhibitor cocktail was added immediately prior to infection. For cell viability
assays, supernatant was collected at the 4-h time point, and LDH was quantified using a CytoTox96 assay
(Promega) per the manufacturer’s instructions. As a positive control, uninfected HTB-9 cells at the end of
the 4 h of incubation were lysed with 1% Triton X-100. Data were expressed as percent lysis of the
positive control.
For HMC-1 killing assays, cells were resuspended in fresh medium at 2 106 cells/ml. Where
applicable, HMC-1 cells were pretreated with 100 M cromolyn sodium as described previously (72) at
37°C with 5% CO2 for 30 min. HMC-1 cells were seeded at 2 105 cells/well in 96-well microtiter plates
with or without 288 ng/ml (64 nM) LL-37. Log-phase COH1 or CFT073 was added at 2 104 CFU in 10 l
for an MOI of 0.1. To facilitate cell-bacterium contact, plates were centrifuged at 300 g for 5 min. Plates
were incubated at 37°C with 5% CO2 for 60 min. Cells were lysed by vigorous pipetting and serial dilution
in water and plated on THB agar. Percent killing was calculated as a percentage of the CFU total from
wells containing bacteria only at the equivalent time point.
qPCR. HTB-9 mRNA was treated with a Turbo DNA-free kit (Invitrogen) per the manufacturer’s
instructions. To synthesize cDNA, approximately 100 ng of total RNA was used with an iScript cDNA
synthesis kit (Bio-Rad). cDNA was diluted 1:2 for real-time qPCR using Kapa SYBR qPCR 2 master mix
(catalog no. KM4101; Kapa Biosystems) and performed on a Bio-Rad CFX96 real-time C1000 thermocycler.
Primers were used at a final concentration of 200 nmol. Primer sequences used for quantification of
human LL-37 mRNA were 5=-GAAGACCCAAAGGAATGGCC-3= and 5=-CAGAGCCCAGAAGCCTGAGC-3= as
described previously (113). The relative transcript level was normalized to the level of the endogenous
housekeeping gene GAPDH using the 2ΔΔCT (where CT is threshold cycle) method (114).
Dot blots. To assess GBS degradation of cathelicidin, stationary GBS cultures were diluted 1:10 in
RPMI 1640 medium, and 100 l per well was added to 96-well microtiter plates. LL-37 or CRAMP was
added at 2 M, a sub-MIC level. Cathelicidin standard curves (100 l volume) at 36, 18, 9, 4.5, 2.3, and
1.1 g/ml, as well as bacterium-only wells, were included as controls. As indicated in figure legends, to
some wells, Halt protease inhibitor cocktail was included at a 1 final concentration. Samples were
incubated at 37°C for 4 h and centrifuged at 3,220 g for 5 min. Supernatant (5 l) was spotted onto
nitrocellulose membranes (catalog no. 162-0214; Bio-Rad) and allowed to dry completely. Membranes
were blocked, with Odyssey blocking buffer diluted 1:1 with PBS for 1 h, with rocking at room
temperature. Mouse anti-LL-37 (HM2071; Hycult) antibody or rabbit anti-CRAMP (pAb-antiCAMP/LL-37,
NB100-98689; Novus) antibody was added at a 1:2,000 dilution and incubated, with rocking, for 2 h at
room temperature. Membranes were washed three times with PBST (PBS with 0.1% Tween 20). Second-
ary goat anti-mouse antibody 680LT (926-68020; Li-Cor) or goat anti-rabbit IgG antibody 800CW
(926-32211; Li-Cor) was added at 1:10,000 and incubated, with rocking, for 30 min at room temperature.
Membranes were washed three times with PBST and two times with PBS and visualized on a Li-Cor
Odyssey instrument. Spot intensity was measured using ImageJ software (NIH, version 1.52a) and
normalized to the level of a 9-g/ml LL-37 control.
Animals. Animal experiments were approved by the University of California (UC) San Diego Institu-
tional Animal Care and Use Committee (IACUC) and conducted under accepted veterinary standards.
Mice were allowed to eat and drink ad libitum. WT C57BL/6J male and female mice, aged 8 to 12 weeks,
originally purchased from Jackson Laboratories, were bred in the same facility along with cathelicidin-
deficient mice (Camp/) on the C57BL/6J background (115). Females were used for UTI and vaginal
colonization studies, and males were used for GBS sepsis studies. WT CD1 female mice, 8 weeks of age,
were purchased from Charles River Laboratories. For studies with exogenous CRAMP treatment, mice
received 50 l of CRAMP (diluted to 1.44 mg/ml in PBS, 72-g total dose) transurethrally 1 h prior to
infection, or control mice received 50 l of PBS, as adapted from prior studies (52). To inhibit mast cell
degranulation, mice were injected i.p. with cromolyn sodium (catalog no. C0399-1G; Sigma-Aldrich) at 10
mg/kg/dose in 100 l at 48 h, 24 h, and 1 h prior to infection, as adapted from prior studies (70). Control
mice were injected i.p. with 100 l of PBS at each treatment time point. To induce diabetes mellitus, mice
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were injected i.p. with streptozotocin (catalog no. AG-CN2-0046-G001; Adipogen) at 80 mg/kg/dose in
200 l of 0.1 M citrate buffer daily for 4 days. Control mice received 4 daily treatments of 200 l of 0.1
M citrate buffer. Mice were weighed weekly thereafter. Blood glucose was determined 24 h prior to
infection, and urinary glucose was determined at 24 h postinfection. Sample glucose was determined
using an AimStrip Plus blood glucose meter kit.
Murine urinary tract infection model. An established mouse UTI protocol was used as previously
described (44). Mice were anesthetized with inhaled isoflurane, and urine was voided from the bladder
prior to transurethral infection with 100 l of GBS COH1 or UPEC CFT073 (administered in 2 to 3 s) at
2 107 CFU per mouse. Transurethral infection was achieved by inserting an UV-sterilized polyethylene
tube (inner dimension, 0.28 mm; outer dimension, 0.61 mm) (catalog no. 598321; Harvard Apparatus)
attached to a 30-gauge hypodermic needle into the urethra. At 24 h postinfection, urine samples were
collected from each mouse prior to euthanasia and removal of bladders and both kidneys. For GBS CFU
enumeration and ELISA, bladders and kidneys were homogenized in PBS containing silica beads
(diameter, 1 mm; Biospec) and shaken at 6,000 rpm for 60 s using a MagNA Lyser (Roche). Homogenates
were serially diluted and plated on THB agar.
Murine vaginal colonization model. Vaginal colonization studies were conducted as described
previously (116). Briefly, mice were synchronized with 0.5 mg of -estradiol administered i.p. 24 h prior
to inoculation. Mice were inoculated with 10 l (2 107 CFU total) of GBS COH1 into the vaginal tract.
The vaginal lumen was swabbed daily, and recovered GBS was quantified by plating on CHROMagar
StrepB.
Murine sepsis model. For sepsis studies, mice were injected with GBS COH1 in 100 l (2 107 CFU)
intraperitoneally as described previously (62). After 24 h, heparinized blood specimens were collected via
cardiac puncture, and kidneys and spleens were homogenized in PBS containing silica beads (diameter,
1 mm) and shaken at 6,000 rpm for 60 s using a MagNA Lyser. Blood and tissue homogenates were plated
on THB agar.
Flow cytometry. Bladder samples were subjected to flow cytometry as adapted from previous work
(44, 117). Bladders were minced finely using a razor blade and then incubated in RPMI 1640 medium with
4 mg/ml collagenase and 50 U/ml DNase for 1 h at 37°C with pipetting every 15 min. Samples were
passed through a 40-m-pore-size filter, and cells were washed in RPMI 1640 medium with 10% FBS.
Cells were blocked with 1:200 mouse BD Fc-block (BD Biosciences) for 15 min on ice in PBS with 1 mM
EDTA, 1% FBS, and 0.1% sodium azide for 15 min on ice. Cells were stained for surface markers using the
following antibodies at 5 g/ml for 30 min on ice: anti-CD11b-fluorescein isothiocyanate (FITC) (clone
M1/70, catalog no. 553310; BD Pharmingen), anti-c-kit-phycoerythrin (PE) (clone 2B8, catalog no. 1880-09;
Southern Biotech), anti-CD11c-PerCP-Cy5.5 (where PerCp is peridinin chlorophyll protein) (clone N418,
catalog no. 45-0114-82; eBioscience), anti-Ly6C-PE-Cy7 (clone HK1.4, catalog no. 25-5932-82;
eBioscience), anti-Ly6G-allophycocyanin (APC) (clone 1A8, catalog no. 127614; BioLegend), anti-MHC-II-
APC-Fire750 (clone M5/114.15.2, catalog no. 107652; BioLegend), anti-FcRI-Pacific Blue (clone MAR-1,
catalog no. 134313; BioLegend), and anti-CD45-BV510 (clone 30-F11, catalog no. 103138; BioLegend).
Samples were gated on unstained cells, and positive signals were determined using single-stain controls.
Samples were run on a BD FACSCanto II (BD Biosciences), and data were analyzed with FlowJo, version
10.2, software (FlowJo LLC).
ELISA. HTB-9 lysates were diluted 1:2 and assessed for LL-37 production using a human LL-37 ELISA
kit (LS-F31974; LSBio) per the manufacturer’s instructions. Murine bladder homogenates were diluted 1:2
and subjected to CRAMP, histamine, and myeloperoxidase quantification using mouse cathelicidin
(LS-F9642; LSBio), histamine (EA31; Oxford), and mouse MPO (DY3667; R&D Systems) ELISA kits per the
manufacturers’ instructions.
Statistics. All data were collected from at least three biological replicates performed in at least
technical duplicate as part of at least two independent experiments. When biological replicates were not
available (e.g., immortalized cell lines and bacterium-only assays), experiments were performed inde-
pendently at least three times. Mean values from technical replicates were used for statistical analyses,
with independent experiment values or biological replicates represented in graphs with means 	
standard errors of the means (SEM) or medians with 95% confidence intervals, as indicated in figure
legends. All data sets were subjected to D’Agostino-Pearson normality test to determine whether values
displayed Gaussian distribution before the appropriate parametric or nonparametric analyses were
selected. In the instances where in vitro, ex vivo, and in vivo experimental numbers (n) were too small to
determine normality, data were assumed to be nonparametric. The alpha level used for all tests was 0.05.
HTB-9 cathelicidin ELISA values were analyzed by Friedman’s test with Dunn’s multiple-comparison test
or by two-way analysis of variance (ANOVA) with Sidak’s multiple-comparison test, as indicated in the
figure legends. GBS growth curves with LL-37 and protease inhibitors were analyzed using two-way
repeated-measures ANOVA with Dunnett’s multiple-comparison test. MIC values for clinical isolates from
different body sites and bladder cathelicidin ELISA of GBS- and UPEC-infected mice were analyzed using
Kruskal-Wallis with Dunn’s multiple-comparison test. Tissue GBS CFU burdens, flow cytometry immune
cell profiles, and mouse body weights were analyzed using two-way repeated-measures ANOVA with
Sidak’s or Tukey’s multiple-comparison test, as indicated in the figure legends. Bladder histamine,
cathelicidin, and MPO ELISAs were analyzed using one-way ANOVA with Holm-Sidak’s or Tukey’s
multiple-comparison tests as indicated in the figure legends. Blood and urine glucose levels and bladder
cathelicidin and histamine ELISA of STZ-treated mice were analyzed by two-tailed Mann-Whitney tests.
Statistical analyses were performed using GraphPad Prism, version 7.03 (GraphPad Software Inc., La Jolla,
CA). P values of0.05 were considered statistically significant.
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